How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
13
LENZ Quote, Financials, Valuation and Earnings
Last price:
$15.82
Seasonality move
:
1.58%
Day range:
$15.64 - $17.77
52-week range:
$14.43 - $50.40
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
25.23x
P/B ratio:
2.55x
Volume:
1.8M
Avg. volume:
1.1M
1-year change:
-37.91%
Market cap:
$495M
Revenue:
--
EPS (TTM):
-$2.11
Analysts' Opinion
-
Consensus RatingLENZ Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $53.71, LENZ Therapeutics, Inc. has an estimated upside of 239.53% from its current price of $15.82.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $36.00 representing -127.56% downside risk from its current price of $15.82.
Fair Value
-
According to the consensus of 6 analysts, LENZ Therapeutics, Inc. has 239.53% upside to fair value with a price target of $53.71 per share.
LENZ vs. S&P 500
-
Over the past 5 trading days, LENZ Therapeutics, Inc. has underperformed the S&P 500 by -22.86% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
LENZ Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
LENZ Therapeutics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter LENZ Therapeutics, Inc. reported revenues of $12.5M.
Earnings Growth
-
LENZ Therapeutics, Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter LENZ Therapeutics, Inc. reported earnings per share of -$0.59.
Enterprise value:
293.8M
EV / Invested capital:
--
Price / LTM sales:
25.23x
EV / EBIT:
--
EV / Revenue:
16.79x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-6.36x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$17.3M
Return On Assets:
-27.55%
Net Income Margin (TTM):
-336.47%
Return On Equity:
-29.1%
Return On Invested Capital:
-28.93%
Operating Margin:
-151.1%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | $17.5M | -- | $12.5M | |
| Gross Profit | -$2.2M | -$37K | $17.3M | -$10K | $12.4M | |
| Operating Income | -$74.2M | -$68.4M | -$67.9M | -$12.9M | -$18.9M | |
| EBITDA | -$72M | -$68.3M | -$67.7M | -$12.9M | -$18.8M | |
| Diluted EPS | -$26.74 | -$88.60 | -$2.11 | -$0.38 | -$0.59 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $401.2M | $298.5M | $238.8M | $220.7M | $207M | |
| Total Assets | $416.2M | $334.8M | $266.2M | $224M | $210.7M | |
| Current Liabilities | $11.3M | $13.5M | $12.5M | $7.7M | $16.3M | |
| Total Liabilities | $16M | $18.4M | $62.2M | $8.7M | $16.8M | |
| Total Equity | $400.1M | $316.5M | $204M | $215.3M | $193.9M | |
| Total Debt | $4.7M | $2.5M | $49.7M | $953K | $461K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$61.8M | -- | -$45.2M | -$10.6M | -$8.6M | |
| Cash From Investing | -$31.3M | -- | $2.3M | -$62.2M | -$4.3M | |
| Cash From Financing | $82.9M | -- | $27.2M | $29.8M | $598K | |
| Free Cash Flow | -$62.9M | -- | -$46.2M | -$10.8M | -$9M | |
LENZ
Sector
Market Cap
$495M
$24.3M
Price % of 52-Week High
31.39%
50%
Dividend Yield
0%
0%
Shareholder Yield
-2.03%
-1.67%
1-Year Price Total Return
-37.91%
-21.43%
Beta (5-Year)
--
0.484
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$19.13
200-day SMA
Sell
Level
$30.26
Bollinger Bands (100)
Sell
Level
18.83 - 39.41
Chaikin Money Flow
Sell
Level
-1.5M
20-day SMA
Sell
Level
$17.77
Relative Strength Index (RSI14)
Sell
Level
36.48
ADX Line
Sell
Level
13.78
Williams %R
Buy
Level
-81.1398
50-day SMA
Sell
Level
$21.29
MACD (12, 26)
Buy
Level
2.36
25-day Aroon Oscillator
Buy
Level
28
On Balance Volume
Sell
Level
-3.1M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (41.7661)
Sell
CA Score
(Annual)
Level (-0.5169)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (6.3972)
--
Piotroski F Score
(Annual)
Level (--)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
LENZ Therapeutics, Inc. is a pre-commercial biopharmaceutical company, which focuses on the development and commercialization of innovative therapies to improve vision. It offers eye drop product treatment for presbyopia. The company was founded by James W. McCollum in July 2013 and is headquartered in Solana Beach, CA.
Stock Forecast FAQ
In the current month, LENZ has received 6 Buy ratings 0 Hold ratings, and 0 Sell ratings. The LENZ average analyst price target in the past 3 months is $53.71.
-
Where Will LENZ Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that LENZ Therapeutics, Inc. share price will rise to $53.71 per share over the next 12 months.
-
What Do Analysts Say About LENZ Therapeutics, Inc.?
Analysts are divided on their view about LENZ Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that LENZ Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $36.00.
-
What Is LENZ Therapeutics, Inc.'s Price Target?
The price target for LENZ Therapeutics, Inc. over the next 1-year time period is forecast to be $53.71 according to 6 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is LENZ A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for LENZ Therapeutics, Inc. is a Buy. 6 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of LENZ?
You can purchase shares of LENZ Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase LENZ Therapeutics, Inc. shares.
-
What Is The LENZ Therapeutics, Inc. Share Price Today?
LENZ Therapeutics, Inc. was last trading at $15.82 per share. This represents the most recent stock quote for LENZ Therapeutics, Inc.. Yesterday, LENZ Therapeutics, Inc. closed at $15.82 per share.
-
How To Buy LENZ Therapeutics, Inc. Stock Online?
In order to purchase LENZ Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get LENZ Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
LENZ
Sector
P/E ratio
--
23.33x
PEG ratio
--
-0.01x
P/B ratio
2.55x
1.78x
Price / LTM sales
25.23x
1.53x
Growth Metrics
LENZ
Sector
Revenue growth
--
4%
Earnings growth
-55.65%
11.06%
Revenue (5-year growth)
--
6.22%
Earnings forecast
-$0.96
-$0.19
Profitability
LENZ
Sector
Profitability FY 2024
-$58K
$3M
Return on invested capital
-28.93%
-33.25%
Return on assets
-27.55%
-29.67%
Return on equity
-29.1%
-38.89%
Earnings Date
Last Earnings Date
Nov
5
Next Earnings Date
Mar
18
Estimated Next Earnings Date
Feb
4
Balance Sheet
LENZ
Sector
Total cash
$202.2M
$25M
Short term investments
$188.9M
$24.9M
Total assets
$215.3M
$72.5M
Long term debt
$461K
$2.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
50
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Sell
40
GDXU alert for Jan 31
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 38.85% over the past day.
Sell
34
PFSI alert for Jan 31
PennyMac Financial Services, Inc. [PFSI] is down 33.21% over the past day.
Sell
40
SHNY alert for Jan 31
MicroSectors Gold 3X Leveraged ETN [SHNY] is down 31.56% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
